Bristol-Myers/Yale R&D agreement
Executive Summary
1982 cooperative cancer R&D agreement has been renewed under original terms. Bristol will provide $3 mil. over five-year period for the "development of anticancer antibiotics, studies on overcoming drug resistance of certain cancer cells, identification of drugs that can convert malignant cells to benign cells, synthesis of new anticancer and antiviral drugs, and tests of promising new drugs in patients with cancer," according to Bristol. The company has a licensing option for drugs discovered under the program.